Tuesday, 19 Mar 2019

You are here

Should Immunoglobulins be Monitored with Rituximab Use?

Boston researchers have found that in a large cohort study of patients receiving rituximab (RTX), most were not being monitored for hypogammaglobulinemia, despite the observed significant increase in severe infections and increased mortality in RTX treated patients.

Published analyses of RTX rheumatoid arthritis clinical trial data has shown that while IgM decreases were common (24%), they were of little consequence. On the other hand, less frequent (4%) IgG decreases, for more than 4 mos. (either before or after RTX),  was associated with a significant increased risk for serious infecions. (Citation source: https://buff.ly/2SSCJRf) RTX trials in granulomatosis with polyangiitis (GPA) found 6 month decreases in immunogloblin levels 27% for IgA, 58% for IgG and 51% for IgM.

A cohort study of 4479 patients receiving RTX (up to 12/31/17) in the in a tertiary, academic Partners HealthCare System examined immunoglobulin measurements, infectious complications, and mortality.

They found that 85% of patients did not have immunoglobulin levels checked before rituximab therapy.

In the 15% with Ig levels assessed hypogammaglobulinemia was found in nearly half (48%) and post RTX, worsening hypogammaglobulinemia was often noted.

There was an increase in severe infections after rituximab use in the study cohort (from 17.2% to 21.7%; P < .001).

Increased mortality was associated with increasing age, male sex and severe infectious complications in the 6 months before and after the first rituximab infusion.

A total of 201 patients (4.5%) received immunoglobulin replacement following rituximab, presumeably for hypogammaglobulinemia.  In this subset, higher cumulative immunoglobulin replacement dose was associated with a reduced risk of serious infectious complications (HR, 0.98; 95% CI, 0.96-0.99; P = .002).

These findings suggest there may be a risk reduction benefit to assessing for hypogammaglobulinemia both before and after rituximab administration. Identification of hypogammaglobulinemic patients (especially with low IgG levels) may prompt the need for immunoglobulin replacement therapy to reduce infectious and mortal risks. 

Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

No Rise in Cancer Risk with Actemra

In patients with rheumatoid arthritis (RA), there was no increased risk for malignancy development seen with newly initiated tocilizumab (Actemra) treatment, an analysis of three U.S. insurance claim databases found.

First Line IL-1 Inhibition in Systemic JIA

First-line treatment of systemic juvenile idiopathic arthritis (JIA) with anakinra (Kineret) was highly effective as monotherapy, minimizing the need for glucocorticoids, a single-center prospective study found.

Impressive Survival of Interleukin-1 Inhibitors in Systemic Juvenile Idiopathic Arthritis

The drug retention rate of interleukin-1 inhibitors (IL-1) used to treat systemic juvenile idiopathic arthritis (JIA) appears to be quite high according to a new study. 

Safety Warnings for Higher Dose Tofacitinib

Pfizer has issued a press release regarding the safety of tofacitinib, citing higher rates of pulmonary embolism and death associated with the use of higher dose tofacitinib 10mg bid in rheumatoid arthritis (RA) patients treated in a long-term safety trial.  

Stopping Biologics Before Joint Surgery: Is Earlier Better?

Withholding intravenous abatacept (Orencia) for longer than a month before hip or knee arthroplasty among patients with rheumatoid arthritis (RA) did not lower the risk for postoperative infection, a retrospective claims-based analysis found.